PL427216A1 - Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów - Google Patents
Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworówInfo
- Publication number
- PL427216A1 PL427216A1 PL427216A PL42721618A PL427216A1 PL 427216 A1 PL427216 A1 PL 427216A1 PL 427216 A PL427216 A PL 427216A PL 42721618 A PL42721618 A PL 42721618A PL 427216 A1 PL427216 A1 PL 427216A1
- Authority
- PL
- Poland
- Prior art keywords
- cytostatic
- pharmaceutical formulation
- selenitetrigliceride
- cancer treatment
- formulation containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Przedmiotem zgłoszenia jest formulacja farmaceutyczna o właściwościach przeciwnowotworowych zawierająca co najmniej jeden cytostatyk oraz seleninotrigliceryd, korzystnie selol jako substancję wzmacniającą działanie cytostatyku do zastosowania w leczeniu nowotworu, przy czym co najmniej jeden cytostatyk oraz selol umieszczone są w nośniku lipidowym.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL427216A PL241189B1 (pl) | 2018-09-27 | 2018-09-27 | Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów |
EP19865889.0A EP3856148A4 (en) | 2018-09-27 | 2019-09-26 | PHARMACEUTICAL FORMULATION CONTAINING A TRIGLYCERIDE SELENITE AND A CYTOSTATIC AGENT FOR USE IN THE TREATMENT OF A TUMOR |
PCT/PL2019/050055 WO2020067910A2 (en) | 2018-09-27 | 2019-09-26 | Pharmaceutical formulation containing a selenitetriglyceride and a cytostatic for use in treatment of tumour |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL427216A PL241189B1 (pl) | 2018-09-27 | 2018-09-27 | Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów |
Publications (2)
Publication Number | Publication Date |
---|---|
PL427216A1 true PL427216A1 (pl) | 2020-04-06 |
PL241189B1 PL241189B1 (pl) | 2022-08-22 |
Family
ID=69953584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL427216A PL241189B1 (pl) | 2018-09-27 | 2018-09-27 | Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3856148A4 (pl) |
PL (1) | PL241189B1 (pl) |
WO (1) | WO2020067910A2 (pl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113713110B (zh) * | 2021-09-22 | 2022-11-15 | 滨州医学院 | 一种药物组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL229503B1 (pl) * | 2015-09-21 | 2018-07-31 | Narodowy Inst Lekow | Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów |
CN107714650A (zh) * | 2016-08-11 | 2018-02-23 | 杭州健昵福生物科技有限公司 | 一种含谷氨酰胺代谢抑制剂脂质体及其药物组合物与用途 |
PL238526B1 (pl) * | 2018-09-04 | 2021-08-30 | Narodowy Inst Lekow | Połączenie izotiocyjanianów z organicznymi związkami selenu w nośnikach leków jako nowy środek farmaceutyczny o aktywności przeciwnowotworowej |
-
2018
- 2018-09-27 PL PL427216A patent/PL241189B1/pl unknown
-
2019
- 2019-09-26 WO PCT/PL2019/050055 patent/WO2020067910A2/en unknown
- 2019-09-26 EP EP19865889.0A patent/EP3856148A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PL241189B1 (pl) | 2022-08-22 |
WO2020067910A3 (en) | 2020-05-14 |
EP3856148A2 (en) | 2021-08-04 |
WO2020067910A2 (en) | 2020-04-02 |
EP3856148A4 (en) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000973A1 (es) | Inhibidores de ras | |
CL2023000974A1 (es) | Inhibidores de ras | |
CL2023000972A1 (es) | Inhibidores de ras | |
CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
SA521422304B1 (ar) | مركبات تشارك في الارتباط التعاوني واستخداماتها | |
EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
EA201890458A1 (ru) | Композиции с усилителями проницаемости для доставки лекарств | |
CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
CO2023016820A2 (es) | Inhibidores de ras | |
GB2568000A (en) | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents | |
SG10201811574YA (en) | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
PL426879A1 (pl) | Połączenie izotiocyjanianów z organicznymi związkami selenu w nośnikach leków jako nowy środek farmaceutyczny o aktywności przeciwnowotworowej | |
MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
PL427216A1 (pl) | Formulacja farmaceutyczna zawierająca seleninotrigliceryd i cytostatyk do zastosowania w leczeniu nowotworów | |
AU2017394032A8 (en) | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
BR112017028012A2 (pt) | Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2 | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
PL414021A1 (pl) | Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. |